Daily Newsletter

29 August 2023

Daily Newsletter

29 August 2023

Orthofix fully commercialises 7D FLASHNavigation System in US

The image-guidance system leverages advanced camera-based technology, along with machine-vision algorithms.

RanjithKumar Dharma August 29 2023

Spine and orthopaedics company Orthofix Medical has fully commercialised its 7D FLASHNavigation System Percutaneous Module 2.0 in the US.

The company has also announced the completion of the first procedures in the country with the system.

Designed to offer new planning features and increased functionality for the 7D FLASH Navigation System, the new module enables the company to better serve the minimally invasive surgery (MIS) spine market.

Leveraging visible light, the system will deliver a three-dimensional image for surgical navigation within seconds.

It is claimed to be the only image guidance system that uses advanced camera-based technology along with machine-vision algorithms.

The machine-vision technology is said to reduce radiation exposure for patients and staff during open procedures.

Orthofix Global Enabling Technologies president Dr Beau Standish said: “This launch expands the clinical functionality and utility of the 7D FLASH Navigation System by providing surgeons with a fully integrated procedural solution for MIS, including implant planning and an expanded offering of navigated tools.

“This new application addresses the important MIS spine navigation market and further positions the 7D FLASH Navigation System to be the navigation choice for a wide range of institutions, from teaching hospitals to ambulatory surgery centres.”

In January 2023, Orthofix merged with SeaSpine to create a new spine and orthopaedics company with several products.

The new entity offers a range of biologics, bone growth therapies, specialised orthopaedic solutions and spinal hardware, besides a surgical navigation system.

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close